TruScreen Achieves Significant Milestones with Distributors

NZX/ASX Announcement
3 March 2022
TruScreen achieves significant milestones with Distributors
Key Highlights
• TruScreen achieves National Pricing Approval in China
• Zimbabwe National Aids Council project generates new SUS sales contract
• Distributors incentivised to boost sales by new share options issue
• Appointment of Marketing and Communications Manager
TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide the
following market update, outlining the Company’s progress.
TruScreen achieves National Pricing Approval in China
In December 2021, The National Health Commission of the People’s Republic of China published an
updated Technical Specification for National Procedures and Services in Medicine on the Healthcare
Standard website. Following a one-month exposure period, these procedures are implemented and
distributed to all Provincial Health Commissions in China.
TruScreen cervical cancer screening system is now included in these guidelines with the result that it
is no longer required for provinces to go through clinical and technical evaluation prior to seeking
National Health Commission’s approval. TruScreen currently has national pricing approval in 7
provinces and a further 10 provincial applications are pending. The inclusion of TruScreen in the
updated Technical Specifications will shorten the purchasing cycle by Provincial Health commissions
and will accelerate the entry of TruScreen cervical cancer screening system in all remaining
provinces.
Zimbabwe places March 2022 order for 10,800 SUS units
TruScreen also announce that the initial pilot phase of the Zimbabwe National AIDS Council cervical
cancer screening project was successfully completed in late calendar year 2021.
The project was highly significant in relation to Zimbabwe’s healthcare challenges, in cervical cancer.
Seven selected clinics screened 500 women over a one-month period. Following the completion of
the initial pilot phase TruScreen secured a sales contract with Zimbabwe National AIDS Council for
10,800 single-use senor (SUS) units to complete the ongoing pilot project.
The link between HIV AIDs and cervical cancer is that women diagnosed with HIV have a higher risk
of later developing cervical cancer. With Zimbabwe having one of the higher HIV rates in the world
and Africa with an above-average rate of cervical cancer, the effective and low-cost Truscreen cervical
screening technology is a key response in its healthcare strategy.
Distributors incentivised to boost sales by new share options issue
TruScreen has today issued 2,250,000 share options to distributors with exercise price of NZ$0.10
and an expiry date of 7 September 2024.

The share options were approved by shareholders at the annual shareholders meeting on 7
September 2021 and issued to seven international distributors. This initiative together with regular
distributor conferences are designed to build the TruScreen distributor community, enabling
distributors to share and leverage off each other’s success. In the process, further aligning their
interests with TruScreen.
Appointment of Marketing and Communications Manager
TruScreen recently appointed Hubert Chan, a senior marketing executive with 15+ years’ experience
in the medical device field, as its Marketing & Communications Manager.
During his time working in the medical device market segment, Hubert held a number of global head
office-, regional- and national-based positions located in Australia, USA, Switzerland and UK. These
roles specialised in pre-launch, launch and post-launch activities for a range of medical device
products, including cochlear implants, orthopaedics, wound management, endoscopy, and surgical
instruments.
Hubert holds a Master of Business Administration from the Australian Graduate School of
Management and a Bachelor of Medical Science (Honours) from the University of Sydney.
Hubert’s skills and experience will drive the Company in marketing strategy, product lifecycle
management and global medical device markets, as the Company further expands the geographic
footprint. The TruScreen technology is ideal for communities unable to access conventional,
laboratory dependent, and other screening methods.

TruScreen CEO Juliet Hull said: “The ability of TruScreen to accelerate pricing approvals in all
provinces of China is a major step forward in our key market. The Zimbabwe contract is also a
validation of the concerted efforts of TruScreen and its distributor network to expand to target markets
overseas.
With an eye to continued growth in our revenue base, we are pleased to launch the international
distributor-specific share options plan that incentivises distributors to bolster TruScreen product sales.
Finally, I would personally like to welcome Hubert to the TruScreen team. He will be a key asset as
the Company continues to grow its geographic footprint.”

This announcement has been approved by the Board.
-ENDS-

For more information, visit

www.truscreen.com or contact:
Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetowrk.com.au

+61 2 8999 3699

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, and Saudi Arabia, where no large-scale cervical cancer
screening programs and infrastructure are currently in place. By doing so, the Company hopes to help
improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/